- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01604291
An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Afula, Israele, 18101
- Haemek Hospital; Gastroenterology
-
Ashkelon, Israele, 78278
- Barzilai MC; Gastroenterology
-
Beer Sheva, Israele, 84105
- Soroka Medical Center; Gastroenterology
-
Hadera, Israele, 38100
- Hillel Yaffe Hospital; Gastroenterology
-
Haifa, Israele, 31096
- Rambam Medical Center; Gastroenterology - Liver Unit
-
Haifa, Israele, 33394
- Bnei-Zion Medical Center; Gastroenterology
-
Haifa, Israele, 34362
- Carmel Hospital; Liver Unit
-
Holon, Israele, 58100
- Wolfson Hospital; Gastroenterology Unit
-
Jerusalem, Israele, 91031
- Shaare Zedek Hospital Liver Unit; Liver Unit
-
Jerusalem, Israele, 91120
- Hadassah Hospital; Liver Unit
-
Kfar Saba, Israele, 44281
- Meir Medical Center; Liver Unit
-
Nahariya, Israele, 22100
- Western Galilee Hospital - Nahariya
-
Nazareth, Israele
- Holy Family Medical Center; Liver Unit
-
Petach Tikva, Israele
- Hasharon Mc; Gastroenterology
-
Petah Tiqwa, Israele
- Beilinson-Rabin Liver Unit; Liver Unit
-
Ramat Gan, Israele, 5262100
- Sheba Medical Center; Tel Hashomer
-
Rehovot, Israele, 76100
- Kaplan Medical Center; Gastroenterology Unit
-
Safed, Israele, 13110
- Rebecca Sieff Medical Center; Liver Unit
-
Tel Aviv, Israele, 6423906
- Tel-Aviv Sourasky Medical Center; Liver Unit
-
Tiberias, Israele
- Poria Hospital; Gastroenterology
-
Zerifin, Israele, 6093000
- Assaf Harofeh; Gastroenterology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Chronic hepatitis C (all genotypes, naïve or treatment experienced, HCV mono-infected or HCV-HIV co-infected)
- Receiving either dual therapy (Pegasys plus ribavirin) or triple therapy (Pegasys plus ribavirin plus telaprevir/boceprevir)
- No contra-indications to Pegasys and ribavirin therapy or to treatment regimen containing protease inhibitor (telaprevir or boceprevir) as detailed in local Prescribing Information
- Quantitative serum HCV RNA by PCR test before initiation of treatment
Exclusion Criteria:
- Hepatitis A/B co-infection
- Evidence of severe illness, active malignancy, or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study
- Pregnant or breast-feeding women
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
---|
Coorte
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants With Sustained Viral Response (SVR) at Week 24
Lasso di tempo: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
|
Week 24
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Comparison of SVR at Week 24
Lasso di tempo: Week 24
|
SVR at Week 24 is compared by treatment group, type of infection, prior treatments and genotype.
|
Week 24
|
Number of Participants With SVR at Week 24 According to the Demographic Characteristics
Lasso di tempo: Week 24
|
The overall SVR-24 rate was defined as percentage of participants with Hepatitis C Virus Ribonucleic Acid (HCV-RNA) levels < 50 International Units per MilliLiter (IU/mL) (as measured by Polymerase Chain Reaction (PCR)) at 24 weeks post treatment completion.
Number of participants analysed signifies participants who were evaluated for outcome measure.
Data for this outcome measure was not summarized for each arm.
Hence, data is reported for all participants.
|
Week 24
|
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
Lasso di tempo: Week 4
|
RVR was defined as HCV-RNA <50 IU/mL by Week 4
|
Week 4
|
Percentage of Participants With Extended RVR
Lasso di tempo: Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Extended RVR was defined as HCV-RNA <50 IU/mL at weeks 4 and 12 for participants treated with telaprevir; or at weeks 8 & 24 for participants treated with boceprevir. The assessment was performed in participants who received triple therapy in treatment arms 'Peginterferon Alfa-2a + Ribavirin +Telaprevir' and 'Peginterferon Alfa-2a + Ribavirin + Boceprevir'. |
Week 4 and 12 for telaprevir group; Week 8 and 24 for boceprevir group
|
Percentage of Participants With Complete Early Virologic Response (cEVR)
Lasso di tempo: Week 12
|
Complete early virologic response (cEVR) was defined as HCV-RNA <50 IU/mL by Week 12
|
Week 12
|
Percentage of Participants With End of Treatment Response (EoT)
Lasso di tempo: Week 24
|
End-of-Treatment (EoT) response was defined as HCV-RNA <50 IU/mL by the end of treatment.
|
Week 24
|
Percentage of Participants With Virologic Relapse
Lasso di tempo: Week 72
|
Virologic relapse was defined as detectable HCV-RNA during the treatment-free follow-up period in participants with HCV-RNA <50 IU/mL at EoT.
|
Week 72
|
Treatment Duration
Lasso di tempo: Week 48
|
The average amount of time a treatment was prescribed to participants.
|
Week 48
|
Time to First Dose Modification of Peginterferon Alfa-2a
Lasso di tempo: Week 48
|
Week 48
|
|
Time to First Dose Modification of Ribavirin
Lasso di tempo: Week 48
|
Week 48
|
|
Time to First Dose Modification of Telaprevir/Boceprevir
Lasso di tempo: Week 48
|
Week 48
|
|
Percentage of Participants With Adverse Events (AEs)
Lasso di tempo: Week 48
|
Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Safety analysis included 2 additional participants in arm 'Peginterferon Alfa-2a + Ribavirin + Telaprevir'. The safety parameters were analyzed by the treatment actually received by the participants. |
Week 48
|
Mean Value of Hemoglobin in Participants With Treatment-Induced Anemia
Lasso di tempo: Week 48
|
Week 48
|
|
Percentage of Participants With Treatment Regimen for HCV Treatment Induced Anemia
Lasso di tempo: Week 48
|
Week 48
|
|
Percentage of Participants Who Had SVR at Week 24 With Dose Modifications
Lasso di tempo: Week 24
|
Participants with dose modifications who had achieved SVR at Week 24 were reported.
Data was collected for all participants who had dose modification of Peginterferon alfa-2a, Ribavirin or Telaprevir/boceprevir in any of the treatment regimen during the study.
|
Week 24
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Flaviviridae Infezioni
- Epatite, virale, umana
- Infezioni da enterovirus
- Infezioni da Picornaviridae
- Epatite cronica
- Epatite
- Epatite A
- Epatite C
- Epatite C, cronica
Altri numeri di identificazione dello studio
- ML28268
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .